KR20140075844A - A composition for the treatment or prevention of osteoarthrits comprising an extract of crinum asiaticum - Google Patents

Abstract

The present invention relates to a composition comprising an alginic acid as an active ingredient to treat or prevent osteoarthritis or osteoporosis, wherein the composition to treat or prevent osteoarthritis or osteoporosis can be a pharmaceutical composition. Furthermore, the present invention relates to a food composition comprising the alginic acid as an active ingredient to alleviate or prevent osteoarthritis or osteoporosis. The present invention has verified the optimum conditions to treat, prevent, or alleviate osteoarthritis or osteoporosis with respect to a molecular weight of the alginic acid, mannuronate, and guluronate; thereby has no side effects by comprising the alginic acid, which is harmless to the human body, as an active ingredient and can valuably be used to treat osteoarthritis or osteoporosis since the therapeutic effect for osteoarthritis or osteoporosis is also superior.

Description

FIELD OF THE INVENTION [0001] The present invention relates to a composition for preventing or treating osteoarthritis comprising alginic acid. [0002] The present invention relates to a composition for prevention or treatment of osteoarthritis,

The present invention relates to a composition for preventing or treating osteoarthritis.

Cartilage is a resilient tissue that connects two bones together, imparts mobility to the joints, and acts as a shock mitigation. In particular, articular cartilage includes cartilage cells embedded in a matrix of proteoglycan and type II collagen as a connective tissue.

If the cartilage tissue is damaged, direct friction between the bones, stiffness of the joint, gradual decrease of the articular cartilage movement, or frequent pain of the cartilage area may be caused.

Joint disease caused by damage to the cartilage tissue, particularly osteoarthritis, is a disease accompanied by loss of cartilage function, and is one of the most common symptoms of arthritis. It is known that many people have symptoms of osteoarthritis.

The osteoarthritis is known by various other names such as degenerative joint disease, osteoarthritis, hypertrophic arthritis or degenerative arthritis. The osteoarthritis may be characterized by chronic progressive destruction of cartilage tissue in major joints such as fingers, elbows, knees or ankles.

Although the initial etiology of osteoarthritis is not clearly known, it is generally known that cartilage destruction is caused by a change or imbalance in the metabolic mechanism associated with assimilation and catabolism in the articular cartilage matrix.

In osteoarthritis such as osteoarthritis, excessive catabolism and lack of assimilation are apparent, resulting in imbalance of metabolic equilibrium. For example, it is known that, when the hyperactivation activity in the articular cartilage matrix exceeds the anabolic activity due to the increase in the catabolic function by the chondrocytes, the total matrix is reduced due to the structural destruction of the proteoglycan and type II collagen have.

It is known that it is very difficult to restore joints that have already developed degenerative changes to normal joints, and it is known that there are limitations in the treatment of osteoarthritis.

Concerning the surgical treatment, in case of arthroscopic surgery, the duration of the effect is not constant. In the case of artificial arthroplasty, the life expectancy of the artificial joint is limited. Therefore, There is a problem that complications such as bleeding or infection may occur in the process.

Until recently, the treatment of osteoarthritis, such as medication therapy through conservative treatment to alleviate symptoms, lifestyle and overweight, such as improving the worsening factors of arthritis to prevent the progression of additional arthritis is mainly done. For example, it is known that administration of a sufficient amount of glucosamine compound can protect or substantially improve the quality of cartilage in the joint showing osteoarthritis. In particular, glucosamine sulfate, one of the basic components of the disaccharide unit of glycosaminoglycan (GAG), has been shown to significantly promote the production of proteoglycan in cartilage cells. However, the glucosamine compound is known to have relatively no effect on the generation of type II collagen.

Therefore, alternative therapies using active ingredients derived from natural materials capable of restoring osteoarthritis or restoring joints have been actively pursued without the other side effects.

Bone tissue is a very complex and active tissue composed of extra cellular matrix composed of minerals such as collagen fiber and hydroxyapatite, and various kinds of cells such as osteoblasts, osteoclasts and osteocytes. Through the action of osteoclasts, it constantly forms and absorbs for a lifetime and progresses through the process of aggregate formation.

The collagen fibers are one of the most important elements constituting the human body and widely distributed not only in bone but also in connective tissues such as dermis, ligament, tendon, cartilage, fascia or blood vessel. The principal component of the collagen fiber is a light fiber protein called collagen. Pyridinoline and dioxypyridinoline, which are mature crosslinks of the collagen, are excreted in the urine when osteoclast destruction is caused by osteoclasts. Since they are mainly present in the bone and cartilage, It has been used clinically as a reliable biomaker for evaluation of bone degradation in various pathological behaviors such as osteoarthritis.

The aggregate formation process includes various growth factors secreted from bone tissues such as hormone such as parathyroid hormone (PTH), calcitonin and estrogen and insulin growth factor I (IGF-I), tumor necrosis factor- And regulates the activity balance of osteoblasts and osteoclasts and maintains homeostasis.

However, when the osteoblast activity is weakened due to changes in genetic, physiological, and environmental factors, osteogenesis is decreased, osteoclast activity is enhanced, osteoporosis is increased, A disease occurs.

Osteoporosis is a typical bone metabolic disorder, which means metabolic bone disease with a major decrease in bone mass, with bone mass being significantly reduced compared to normal people of the same age and sex. Riggs and Melton et al classified osteoporosis after age 50 as Type 1 osteoporosis (postmenopausal osteoporosis) or primary osteoporosis and type 2 osteoporosis (senile osteoporosis) or secondary osteoporosis .

The menopausal osteoporosis refers to osteoporosis caused by estrogen deficiency, which is a condition in which fracture can easily occur due to estrogen deficiency due to a decrease in bone mineral content and changes in the composition of collagen fibers.

As a treatment for osteoporosis, currently calcium supplement, vitamin D metabolite and thiazide diuretic therapy, calcitonin therapy, bisphosphonate therapy and estrogen therapy have been used. However, Osteoporosis is more important than prevention because of the lack of drugs.

In addition, estrogen-like substances used for the treatment of postmenopausal osteoporosis may cause side effects such as nausea, weight gain, irregular uterine bleeding, endometrial cancer and breast cancer in long-term use. Recently, There have been active researches on alternative therapies using active ingredients derived from natural materials such as herbal medicines and foods that can promote bone formation while minimizing bone loss.

Alginic acid, alginate, is a mixture of α-L-guluronate and C5 epimer with 1,4-β-D-mannuronate, 4 conjugated or β-1,4-linked heteropolysaccharide, which is a complex sugar polymer bound in the form of pG block (polyguluronate block), pM block (polymannuronate block) and pM / G stretch.

Since alginic acid mainly constitutes a cell wall of brown algae, it can be obtained by extraction from brown algae. Alginic acid has been extensively used since ancient times because of its unique physical properties such as gel-forming ability, high viscosity and film forming ability.

It is used as a stabilizer, viscous agent or gelling agent in various industrial fields including, for example, the food industry, the printing industry and the pharmaceutical industry and is used as a raw material for drug delivery systems such as microparticles, beads, microcapsules or tablets, Carrier and the like.

In addition, alginic acid has been reported to exhibit various physiological activities such as obesity suppression, constipation healing by promoting intestinal peristalsis movement, inhibition of cholesterol, absorption and elimination of heavy metals in the body, or toxicity of harmful substances, Research is underway to utilize it.

In addition, it is known that it has a physiological activity effect such as wound covering material for protecting wounds and hemostasis. Recently, it has been known that oligosaccharide derived from alginate has various biological control functions such as antimicrobial / anticancer effect, immunity enhancement, anticholesterol effect, Respectively.

KR 10-1177009 B KR 10-0840988 B KR 10-0740169 B

The present invention provides a composition for treating, ameliorating or preventing osteoarthritis, which comprises a natural substance harmless to human body as an effective ingredient.

In order to achieve the above object, the present invention provides a composition for treating or preventing osteoarthritis or osteoporosis comprising alginic acid as an active ingredient.

The alginic acid may have an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000, preferably 2,400 to 2,600.

The alginic acid may have an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000 and a weight ratio (M / G) of mannuronate of alginic acid to gluronate of 2.0 to 3.4, preferably 2.3 to 2.7 .

The alginic acid may be one having a weight ratio (M / G) of mannuronate of alginic acid and gluronate of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.3 to 2.7.

The present invention also provides a food composition for preventing or ameliorating osteoarthritis or osteoporosis comprising alginic acid as an active ingredient. The food composition may be food, food additive or beverage.

The alginic acid may have an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000 and a weight ratio (M / G) of mannuronate of alginic acid to gluronate of 1.6 to 3.8.

The alginic acid may have an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000, preferably 2,400 to 2,600.

The alginic acid preferably has an average weight average molecular weight (Mw) of alginic acid of 1,500 to 5,000, a weight ratio (M / G) of mannuronate of alginic acid to gluronate of 1.6 to 3.8, preferably 2.0 to 3.4, Preferably 2.3 to 2.7.

The alginic acid may be one having a weight ratio (M / G) of mannuronate of alginic acid and gluronate of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.3 to 2.7.

Further, the present invention provides a use of alginic acid, specifically for the treatment, improvement or prevention of osteoarthritis or osteoporosis of alginic acid.

The alginic acid may have an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000, preferably 2,400 to 2,600.

The alginic acid preferably has an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000, a weight ratio (M / G) of mannuronate of alginic acid to gluronate of 1.6 to 3.8, preferably 2.0 to 3.4, May be 2.3 to 2.7.

The alginic acid may be one having a weight ratio (M / G) of mannuronate of alginic acid and gluronate of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.3 to 2.7.

Hereinafter, the present invention will be described in more detail.

The present inventors have searched for substances derived from natural materials capable of promoting the production of collagen and proteoglycan while studying substances derived from natural products that have therapeutic, ameliorative or preventive effects of osteoarthritis or osteoporosis with secured human safety, In the case of alginate, which is a natural product that can be extracted from brown algae in the process, the molecular weight and the ratio of mannuronate (M) to guluronate (G) constituting the alginic acid constitute the ability to promote collagen production and the production of proteoglycan It was confirmed that the promoting ability was different.

Specifically, when the weight average molecular weight (Mw) is 2,500, the production of collagen and proteoglycan is remarkably promoted as compared with the case where the weight average molecular weight is 98,000, and mannuronate (M) and glue It was confirmed that the ratio of guluronate (G) in the range of 2.5 to 3.2, most preferably 2.5, based on the weight ratio, was the best in promoting collagen production and promoting the production of proteoglycan. Further, As a result, it was found that the ratio of the gluconate to mannuronate was 2.5: 1 (mannuronate: gluronate) to 3.2: 1 (mannuronate: gluronate) It is confirmed that alginic acid, which is preferably 2.5: 1 (mannuronate: gluronate), has the best effect of improving joint damage, The.

The present invention relates to a composition for treating or preventing osteoarthritis or osteoporosis comprising alginic acid as an active ingredient.

The alginic acid may have an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, and still more preferably 2,400 to 2,600.

The molecular weight (g / mol) may be an average molecular weight, and the measured molecular weight is a weight average molecular weight (Mw).

The alginic acid preferably has a ratio of mannuronate (M) to guluronate (G) of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2, 2.5 to 3.2 or 2.3 to 2.7, and most preferably 2.5.

In this sense, the alginic acid is a mixture of guluronate (G) and mannuronate (M) based on the ratio of mannuronate (M) to guluronate (G) (Mannuronate: glutarate), preferably 2.0 to 3.4: 1 (mannuronate: gluronate), more preferably 2.2 to 3.2: 1 (Mannuronate: gluconate) or 2.3 to 2.7: 1 (mannuronate: gluronate), most preferably 2.5: 1 (mannuronate: Gluconate).

In addition, the alginic acid has a weight average molecular weight (Mw) of 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, still more preferably 2,400 to 2,600, the ratio of mannuronate M to guluronate G is in the range of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2, still more preferably 2.5 to 3.2 or 2.3, 2.7, and most preferably 2.5.

The alginic acid of the present invention may contain, in addition to the above components, a nutrient, a vitamin, an electrolyte, a flavoring agent, a coloring agent, a stabilizer, a pectic acid and a salt thereof, an alginic acid and its salt, an organic acid, a protective colloid thickener, An alcohol, a carbonating agent used in a carbonated beverage, and the like. The above-mentioned components may be added to the composition containing the alginic acid independently or in combination. The content of the additional component may be preferably in the range of 0.1 to 20,000 parts by weight per 100 parts by weight of the alginic acid.

In the present invention, osteoarthritis refers to a disease in which inflammation and pain are caused by damage to the bones and ligaments of the joint due to premature damage or degenerative changes of the cartilage protecting the joints.

In the present invention, osteoarthritis may include degenerative arthritis, rheumatoid arthritis, osteoarthritis or degenerative joint disease, for example degenerative arthritis.

It is known that the osteoarthritis is caused by cartilage destruction due to the change or unbalance of the metabolic mechanism associated with anabolic and catabolic activities in the articular cartilage matrix. For example, it is known that, when the hyperactivation activity in the articular cartilage matrix exceeds the anabolic activity due to the increase in the catabolic function by the chondrocytes, the total matrix is reduced due to the structural destruction of the proteoglycan and type II collagen have.

In connection with the progression of osteoarthritis, the production of nitrogen monoxide which causes inflammation in the cartilage matrix and the production of interleukin-1 (IL-1) or matrix metalloproteinases (MMPs) By suppressing or destroying the formation of squares, the cartilage matrix is adversely affected, resulting in accelerated degeneration of the osteoarthritis or the development or progression of osteoarthritis.

The degenerative arthritis is a degenerative non-inflammatory disease that occurs in the osteoarthritis, and the degenerative arthritis is classified into idiopathic arthritis or secondary arthritis.

The idiopathic arthritis is caused by factors such as age, gender, genetic factors, obesity or specific joint site without any specific organic causes, and is called primary arthritis. The secondary arthritis is caused by trauma, disease and deformity that can damage the articular cartilage. It refers to the case where articular cartilage is destroyed by bacterial arthritis or tuberculous arthritis, or after severe shock or repeated light trauma , Secondary arthritis.

In the present invention, osteoporosis is also referred to as osteoporosis or osteoarthritis. It refers to a metabolic bone disease in which bone mass is significantly reduced compared with normal persons of the same age and sex, and the main lesion is the quantitative reduction of bone constituents.

In the present invention, the osteoporosis may include menopausal osteoporosis, senile osteoporosis, and osteoporosis, preferably menopausal osteoporosis.

The osteoporosis mainly involves a phenomenon in which bone is thinned and weakened owing to a decrease in bone tissue and a decrease in calcium salt. Therefore, patients with osteoporosis will have bone fractures.

The osteoporosis, particularly postmenopausal osteoporosis, is known to be associated with a decrease in estrogen secretion. More specifically, in a menopausal state in which menstruation does not occur, secretion of estrogen, a female hormone, is reduced. The decrease in the secretion amount of estrogen increases the activity of osteoclasts in the bone, thereby promoting bone destruction. Reduce calcium precipitation, and reduce the amount of collagen produced.

More specifically, the supply of calcium (Ca) and the synthesis of collagen are indispensably required for bone formation. However, in the case of menopausal osteoporosis in women, And it is reported that inhibition of collagen synthesis due to lack of estrogen is caused by the inhibition of calcium rather than calcium deficiency.

In other words, when estrogen is inadequate due to menopause, the synthesis of collagen is decreased and the bone resorption of calcium is decreased, so that it is reported that osteoporosis can be caused by increased bone resorption. Therefore, it has been reported that menopausal osteoporosis can not be cured by simple dietary calcium intake.

Alginic acid having a ratio of alginic acid of the invention, specifically mannuronate (M) to guluronate (G) of 2.5 or 3.2, is the corresponding mannuronate (M) and guluronate (G) Of alginic acid having a ratio of less than 2.5 or more than 3.2 was found to be superior in osteoarthritis improving function and osteogenesis function. Specifically, it was confirmed through the chondrocyte that collagen synthesis and proteoglycan synthesis could be promoted, and it was confirmed that the regeneration of bone tissue could be improved by using an experimental animal that caused osteoarthritis.

The composition for preventing or treating osteoarthritis or osteoporosis of the present invention may contain 0.001 to 99.99% by weight, preferably 0.1 to 99% by weight, of the alginic acid based on the total weight of the composition. The prevention or treatment of osteoarthritis or osteoporosis The content of the active ingredient can be appropriately controlled depending on the method of use and the intended use of the composition.

The composition may contain, in addition to alginic acid, a nutrient, a vitamin, an electrolyte, a flavoring agent, a coloring agent, a thickening agent, a pectic acid and a salt thereof, an alginic acid and its salt, an organic acid, a protective colloid thickening agent, a pH adjusting agent, a stabilizer, a preservative, glycerin, A carbonating agent used in beverages, and the like. The components may be added to the composition independently or in combination. The content of the additional component is preferably in the range of 0.1 to 20 parts by weight per 100 parts by weight of the alginic acid.

The composition for treating or preventing osteoarthritis or osteoporosis comprising the alginic acid as an active ingredient may be a pharmaceutical composition or a pharmaceutical composition for treating or preventing osteoarthritis or osteoporosis.

In this respect, the present invention may be a pharmaceutical composition containing the alginic acid as an active ingredient and having an effect of treating or preventing osteoarthritis, osteoarthritis, osteoarthritis or osteoporosis-related diseases.

The pharmaceutical composition for treating or preventing osteoarthritis, osteoarthritis, osteoarthritis or osteoporosis-related diseases comprising the alginic acid of the present invention as an active ingredient may contain 0.001 to 99.99% by weight, preferably 0.1 to 99% by weight, of the alginic acid based on the total weight of the composition .

The composition for preventing or treating osteoarthritis or osteoarthritis, osteoarthritis or osteoporosis-related diseases may further comprise suitable carriers, excipients and diluents conventionally used in the production thereof.

The pharmaceutical composition for preventing or treating osteoarthritis, osteoarthritis, osteoarthritis or osteoporosis-related diseases containing the alginic acid as an active ingredient may be formulated into oral dosage forms such as powders, granules, tablets, suspensions, emulsions and syrups by conventional methods Can be used.

Examples of carriers, excipients and diluents that can be contained in a pharmaceutical composition for preventing or treating osteoarthritis, osteoarthritis, osteoarthritis or osteoporosis-related diseases comprising the alginic acid as an active ingredient include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol , Maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium Stearate and mineral oil.

When the pharmaceutical composition for preventing or treating osteoarthritis, osteoarthritis, osteoarthritis or osteoporosis-related diseases comprising the alginic acid as an active ingredient is a solid preparation for oral administration, it includes tablets, pills, powders, granules, capsules and the like. The solid preparation is prepared by mixing at least one excipient such as starch, calcium carbonate, sucrose, lactose, gelatin and the like in the above extract. In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.

When the pharmaceutical composition for preventing or treating osteoarthritis, osteoarthritis, osteoarthritis or osteoporosis-related diseases is a liquid preparation for oral administration, the liquid preparation includes suspensions, solutions, emulsions and syrups. Water, liquid paraffin, which is a simple diluent, and various excipients such as wetting agents, sweeteners, fragrances, preservatives, and the like.

The preferred dosage of the pharmaceutical composition for preventing or treating osteoarthritis or osteoarthritis, osteoarthritis or osteoporosis-related diseases containing the alginic acid as an active ingredient varies depending on the condition and body weight, degree of disease, drug form, administration route and period, And the like. Preferably 0.0001 to 1000 mg / kg per day based on the alginic acid of the present invention, and 0.01 to 100 mg / kg per day for more effective administration, but the present invention is not limited thereto. The administration may be carried out once a day or divided into several times. The dose is not intended to limit the scope of the invention in any way.

In another aspect, the present invention may be a food composition containing the alginic acid as an active ingredient and having an effect of improving or preventing osteoarthritis, osteoarthritis, osteoarthritis or osteoporosis-related diseases.

The alginic acid contained as an active ingredient in the food composition may have an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, still more preferably 2,400 to 2,600 have.

The molecular weight (g / mol) may be an average molecular weight, and the measured molecular weight is a weight average molecular weight (Mw).

The alginic acid preferably has a ratio (M / G) of mannuronate (M) to guluronate (G) of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2 , Even more preferably 2.5 to 3.2 or 2.3 to 2.7, and most preferably 2.5.

Specifically, alginic acid as an active ingredient in the food composition has a weight average molecular weight (Mw) of 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, still more preferably 2,400 to 2,600, The ratio (M / G) of the mannuronate (M) to the guluronate (G) constituting the alginic acid is 1.6 to 3.8, preferably 2.0 to 3.4, 2.2 to 3.2, still more preferably 2.5 to 3.2 or 2.3 to 2.7, most preferably 2.5.

As used herein, the term " food " means a natural product or a processed product containing one or more nutrients. Preferably, it means that the food can be directly eaten through a certain degree of processing. It is intended to include food, food additives, health functional foods and beverages.

Foods to which the alginic acid of the present invention can be added include, for example, various foods, beverages, gums, tea, vitamin complexes, and functional foods. In addition, in the present invention, the food may contain special nutritional foods (e.g., crude oil, spirits, infant food, etc.), meat products, fish products, tofu, jelly, noodles (Such as soy sauce, soybean paste, hot pepper paste, mixed sauce), sauces, confectionery (eg snacks), dairy products (eg fermented milk, cheese), other processed foods, kimchi, pickled foods But are not limited to, fruits, vegetables, beverages, fermented beverages, etc.), natural seasonings (e.g., ramen soup, etc.).

The food, beverage or food additive may be prepared by a conventional production method.

In the present invention, the functional food refers to a food group which is imparted with added value to function and express the function of the food by using physical, biochemical, biotechnological techniques and the like, the regulation of the biological defense rhythm of the food composition, Means a food which is processed and designed so that the body control function regarding the body is sufficiently expressed to the living body.

The functional food may include a food-acceptable food-aid additive, and may further comprise suitable carriers, excipients and diluents conventionally used in the production of functional foods.

In the present invention, beverage is a generic term for drinking or enjoying a taste, and is intended to include functional beverages.

The beverage has no particular limitation on the ingredients other than the alginic acid as an active ingredient as an essential ingredient in the indicated ratios and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary drinks.

Examples of such natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above .

The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably 5 to 12 g per 100 ml of the composition of the present invention. In addition, the composition of the present invention may further contain flesh for the production of natural fruit juice, fruit juice drink, and vegetable drink.

In addition to the above-mentioned composition, the composition of the present invention can be used as a flavoring agent such as various nutrients, vitamins, minerals (electrolytes), synthetic flavors and natural flavors, coloring agents and aggravating agents (cheese, chocolate etc.), pectic acid and its salts, Salts, organic acids, protective colloid thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated beverages and the like.

These components can be used independently or in combination. The proportion of such additives is not so critical, but may be selected in the range of 0 to 20,000 parts by weight per 100 parts by weight of the alginic acid of the present invention.

The functional beverage according to the present invention can be used to control the bio-defense rhythm of the beverage group or beverage composition to which the added value is imparted so that the function of the beverage acts on the specific purpose by physical, biochemical, biotechnological, Means a beverage which has been designed so that the body control function related to restoration and the like is sufficiently expressed in the living body.

The functional beverage is not particularly limited to the other ingredients other than the alginic acid of the present invention as an essential ingredient in the indicated ratios and may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages.

Examples of such natural carbohydrates include monosaccharides such as glucose, fructose, and the like; Disaccharides such as maltose, sucrose, and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above .

The ratio of the natural carbohydrate may generally be about 1 g to 20 g, preferably 5 g to 12 g per 100 ml of the composition of the present invention.

Also, in a food composition for the purpose of improving or preventing osteoarthritis or osteoporosis, the amount of the alginic acid may be 0.01 to 15% by weight of the total food, and the beverage composition may contain 0.02 g 5 g, preferably 0.3 g to 1 g.

The present invention also relates to the use of alginic acid, specifically for the treatment, improvement or prevention of osteoarthritis or osteoporosis of alginic acid.

The alginic acid may have an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000, preferably 2,400 to 2,600.

The alginic acid preferably has an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000, a weight ratio (M / G) of mannuronate of alginic acid to gluronate of 1.6 to 3.8, preferably 2.0 to 3.4, May be 2.2 to 3.2, still more preferably 2.5 to 3.2 or 2.3 to 2.7, most preferably 2.5.

The alginic acid is preferably used in an amount of 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2, still more preferably 2.5 to 3.2 or 2.3, in weight ratio (M / G) of mannuronate of alginic acid to gluronate 2.7, and most preferably 2.5.

The alginic acid, specifically, has a weight average molecular weight (Mw) of 1,500 to 5,000, preferably 2,000 to 4,000, more preferably 2,000 to 3,000, still more preferably 2,400 to 2,600, The ratio of mannuronate (M) to guluronate (G) is 1.6 to 3.8, preferably 2.0 to 3.4, more preferably 2.2 to 3.2, still more preferably 2.5 to 3.2 or 2.3, To 2.7, and most preferably 2.5, exhibit remarkably superior collagen production promoting ability and proteoglycan production promoting ability in cartilage cells compared with alginic acid having a different range of molecular weight or a different ratio of mannuronate to glutarate Osteoarthritis such as degenerative osteoarthritis or osteoarthritis such as osteoarthritis or osteoarthritis, The use for the treatment, improvement or prevention of the related diseases is evaluated as excellent.

The alginate of the present invention was tested using chondrocyte cells and found that the alginic acid had remarkably superior collagen synthesis promoting ability and proteoglycan synthesis promoting ability compared with alginic acid having a molecular weight or a weight ratio of mannuronate and gluronate in different ranges, , It was confirmed that osteoarthritic improvement ability was remarkably excellent. Alginic acid, which is an effective ingredient, can be prepared from brown algae, which is a seaweed used as food, and it is expected that there will be no problem about side effects, Or osteoporosis, and the like.

1 to 6 are photographs showing the improvement of osteoarthritis of experimental animals according to the kind of alginic acid according to an embodiment of the present invention. Fig. 1 is a control group administered with placebo, Fig. FIG. 3 is a photograph of the joint surface of the thigh of an experimental animal to which alginate having a weight ratio (M / G) of 1.0 g of mannose is administered. FIG. 3 is a photograph showing the weight ratio (M / G) of mannuronate- FIG. 4 is a photograph of the joint surface of the thigh of an experimental animal to which alginate with 1.6 was administered, and FIG. 4 is a photograph of the joint surface of an experimental animal administered with alginic acid having a weight ratio (M / G) of 2.5 of mannuronate to glutarate FIG. 5 is a photograph of the joint surface of the thigh of an experimental animal to which alginate having a weight ratio (M / G) of 3.2 of mannuronate to gluronate of alginic acid was administered. FIG. Figure 6 is a graph showing the effect of mannuronate < RTI ID = 0.0 > The weight ratio of agent (M / G) is a photograph taken of the femoral articular surface of the experimental animals treated with 3.8 of alginic acid.

Hereinafter, preferred embodiments of the present invention will be described. The following examples are for illustrative purposes only and are not intended to limit the scope of the invention.

Example  1: Preparation of alginate oligosaccharide

150 g of sodium alginate (Hyundai Chemical Co., Ltd.) having a weight average molecular weight (Mw) of 100,000 to 500,000 was added to 3,000 ml of distilled water using a 5 L fermentation tube, and sodium alginate was completely dissolved to prepare an aqueous solution of sodium alginate Respectively.

15 mg (3,500 unit / g) of alginate lyase (Sigma, USA) was added to the fermentation tube and the digestion reaction was performed for 20 hours.

After the decomposition reaction, the temperature of the fermentation tube was raised to 90 ° C to stop the decomposition reaction by the enzyme, and the cooling water was circulated to cool the aqueous sodium alginate solution which had undergone the enzyme reaction. Filtration was performed using an ultrafiltration membrane (Millipore UF filtration, MWCO 10,000) to obtain alginic acid according to the molecular weight range from the alginic acid aqueous solution having undergone the decomposition reaction by the enzyme.

The molecular weight of the alginic acid obtained by the ultrafiltration membrane was measured by GPC (Gel Permeation Chromatography), and it was confirmed that the mass average molecular weight (Mw) of the alginic acid was 2,500.

The ratio of mannuronate (M) to guluronate (G) was measured on the basis of the weight ratio of alginic acid having an alginic acid mass average molecular weight (Mw) of 98,000 and 2,500, respectively.

The weight ratio (M / G ratio) of the mannuronate of the alginic acid to the gluconate was changed from alginate to poly-mannuronic acid (PMA) and polyguluronic acid (PGA) After the lyophilization, the weight was measured, and then the weight ratio (M / G weigh ratio) of mannuronate and gluronate was determined.

Partial acid hydrolysis of poly-mannuronic acid (PMA) and poly-guluronic acid (PGA) was performed using the method of Mahesh et al.

Specifically, 5 g of alginic acid was added to 0.25 MH ₂ SO ₄ The alginic acid was dissolved well and heated at a maximum power (700 W) for 4 minutes using a microwave (Microwave, MR-208, LG Electronics, Korea). The heated alginic acid solution was cooled to room temperature, and then filtered using a filter paper (Whatman No. 4). After filtration, the residue obtained was dissolved in 0.1 M Na ₂ CO ₃ . The pH of the solution was adjusted to pH 2.85 using 0.1 M HCl, and poly-guluronic acid (PGA) was obtained by centrifuging the precipitate to recover the precipitate. After the centrifugation, the resulting supernatant was adjusted to pH 1.5 with 0.1 M HCl, and the precipitate was recovered by centrifugation. The precipitated poly-mannuronic acid (PMA ).

The obtained polyglucuronate and polymannuronate were each neutralized to pH 7.0 and then lyophilized at -80 ° C to measure the weight of each thereof. The weight ratio of mannuronate to glucuronate (M / G ratio ).

Example  2: Chondrocyte culture

Cartilage was collected from the knee joints of a 2-week-old rabbit (Korea Life Science Research Institute, Korea), and the cartilage collected in 1.6 ml of serum-free DMEM (Pharmacia Biotech. USA) was dipped in 1 ml of 1% collagenase (Sigma, USA).

The culture solution containing the collagenase-added cartilage was placed in a CO ₂ incubator at 37 ° C and the reaction was continued for about 6 hours while shaking the cells every 30 minutes to decompose the collagen in the cartilage tissue into collagenase, Chondrocytes of cartilage tissue were isolated by single cell unit. After performing the above procedure, the culture medium containing the cartilage was centrifuged to discard the supernatant, and 1 ml of complete medium (serum-containing DMEM) was diluted in 2 ml of normal culture medium (10% FBS DMEM) per rabbit To prepare a cell suspension.

The cell suspension was counted and diluted with normal medium (10% FBS DMEM) to a cell density of 0.5 x 10 ⁵ cells / cm ^{2. The} cell culture prepared by diluting the cell suspension was added to each dish After dispensing, it was used for the experiment.

Example  3: Effect of alginate type II collagen synthesis

(Average molecular weight: 2,500, M / G ratio: 1.6) and polymeric alginic acid (average molecular weight: 98,000, M / G ratio: 1.6) were added to each of the dishes containing the chondrocyte- Treated alginic acid was treated with 100 mg / L of the above alginic acid, and then treated with the low molecular weight alginic acid and the high molecular weight alginic acid treated group in the low molecular weight alginic acid treatment group and the high molecular weight alginic acid treated group, And cultured in a CO ₂ incubator at 37 ° C for 48 hours. After the culture, Western blotting was performed using an antibody against collagen (Chemicon international, USA) (Peter B. Kaufman et al ., Molecular and Cellular Methods DNA and Medicines, 108-121, CRCpress).

The amount of the expressed protein was confirmed using the obtained film as a result of the Western blotting, and the quantities of the proteins expressed using the image J 2.0 program (Quantity One ^® BIO-RAD, USA) Type Ⅱ collagen and β-actin used as an internal control were determined, and β-actin was determined as a reference for each protein. The amount of type II collagen and β-actin in the sample in the control group was determined by calibrator. The above experiment was repeated three times in total, and the quantitative results of the above-mentioned three repetitions are shown in Table 1 below.

division Control group Polymeric alginic acid Low molecular weight alginic acid Relative Expression Level
(Collagen type II / actin) 1.11 1.21 2.52 0.85 1.10 2.74 1.05 1.11 2.65

As shown in Table 1, it was confirmed that the expression of type II collagen by chondrocytes in the low molecular alginate-treated group was remarkably increased compared to that of the control group. However, when the polymeric alginate was treated, it was confirmed that the expression of type II collagen was hardly changed in comparison with the control.

From the above results, it was confirmed that the low molecular weight alginic acid activated chondrocytes to improve the type II collagen synthesis, while the polymeric alginic acid had insufficient effect on the type II collagen synthesis.

Example  4: Alginic acid Of proteoglycans  Effect on synthetic enhancement

(Untreated group), a low molecular weight alginic acid treatment group and a high molecular weight alginic acid treatment group as in the case of the above Example 3 in order to analyze the effect on the synthesis of the proteoglycan forming the cartilage matrix according to the molecular weight of alginic acid, The amount of proteoglycan was measured by an Alcian Blue staining assay.

Specifically, as in Example 3, the control group was subjected to no treatment, the low molecular weight alginic acid treatment group and the high molecular weight alginic acid treatment group were treated with the above alginic acid at a concentration of 100 mg / L, The polymer alginate treatment group was cultured in a CO ₂ incubator at 37 ° C for 48 hours, and the OD value of the culture solution was measured. The above experiment was repeated three times in total, and the quantitative results of the above-mentioned three repetitions are shown in Table 2 below.

division Control group Polymeric alginic acid Low molecular weight alginic acid The proteoglycan concentration (OD) 0.245 0.255 0.345 0.235 0.231 0.386 0.263 0.268 0.441

As shown in Table 2 above, the Alcian blue staining method was used to measure the proteoglycan, which is a matrix molecule of cartilage matrix. As a result, the amount of the proteoglycan was remarkably increased in the low molecular weight alginic acid treatment group compared with the control group. It was confirmed that the amount of proteoglycan was not significantly increased.

From the above results, it was confirmed that the low molecular weight alginic acid promotes the synthesis of proteoglycan by chondrocyte cells, while the polymeric alginic acid does not affect the synthesis of proteoglycan.

Example  5: Effect of alginate on the enhancement of collagen synthesis by M / G ratio

The ratio of mannuronate (M) to guluronate (G) constituting the alginic acid in the low molecular alginic acid (mass average molecular weight (Mw) 2,500) confirmed to promote collagen synthesis in Example 3 (M / G) of glutenate and mannuronate, and the following experiment was conducted to confirm the collagen synthesis performance according to the weight ratio (M / G).

First, each alginic acid was treated with a dish containing the chondrocytes as in Example 3, and a control group (untreated group) in which no sample was treated and low molecular weight alginic acid having an M / G ratio of 1.1, 1.6, 100 ㎎ / L. The cells were treated with low molecular weight alginic acid and incubated at 37 ℃ for 48 hours in CO ₂ incubator. Western blotting was carried out in the same manner as in Example 3, and the amount of collagen to the amount of β-actin used as an internal control was measured. Each protein of the control group was determined as a calibrator and quantified. The expression level of type II collagen was measured according to the weight ratio (M / G) of mannuronate to glutonate, and is shown in Table 3.

division Control group Low molecular weight alginic acid M / G ratio 1.1 1.6 2.1 2.5 3.2 3.8 Relative Expression Level
(Collagen type II / actin) 1.02 1.04 1.87 2.15 2.74 2.81 1.90 0.98 1.15 1.75 2.25 2.61 2.57 1.94 0.94 1.21 1.81 2.14 2.71 2.70 1.89

As shown in Table 3, it was confirmed that when low-molecular alginic acid was added to the control group, the amount of collagen synthesis was increased. Particularly, the amount of collagen synthesis increases as the weight ratio (M / G) of mannuron to gluconate is increased compared with that of alginic acid. Alginic acid having a weight ratio (M / G) of glucuronate of alginic acid and mannuronate of 2.5 (M / G) of alginic acid to gluconate was 3.2, and the weight ratio (M / G) of alginic acid to glutarate of alginic acid was 2.5 , But it was confirmed that the amount of collagen synthesis was significantly reduced again at a weight ratio (M / G) of 3.8 to the ratio of alginic acid to glucuronate to mannuronate.

From the above results, it was confirmed that the weight ratio (M / G) of gluconate to mannuronate in the range of 1.6 to 3.8 was higher than that in the case of adding no alginic acid or polymer alginic acid as confirmed in Example 3, The weight ratio (M / G) of gluconate to mannuron to be suitable for promoting the production of collagen synthesis amount was remarkably superior to that in the case where the weight ratio (M / G) was out of the above range in the range of 2.5 to 3.2, The weight ratio (M / G) of neuronate was found to have the best collagen production promoting ability in the case of 2.5.

Example  6: Depending on the M / G ratio of alginic acid Of proteoglycans  Effect on synthetic enhancement

The effect of the low molecular weight alginic acid of the present invention on the synthesis of proteoglycans forming a cartilage matrix was analyzed. Alcian Blue staining assay was performed to measure the amount of proteoglycan.

(Mannuronate, M) and guluronate (alginate) constituting alginic acid as in Example 5 were obtained from low molecular alginic acid (mass average molecular weight (Mw) 2,500) confirmed to promote the production of proteoglycan in Example 4 above. , G) to determine the proteoglycan production promoting ability according to the weight ratio (M / G).

First, the control group (untreated group) treated with no sample as in Example 5, and the low-molecular alginic acid group with M / G ratio of 1.1, 1.6, 2.1 and 2.5 were treated with 100 mg / Were cultured in a CO ₂ incubator at 37 ° C for 48 hours. The OD value of the culture solution after the culture was measured as in Example 4, and the results are shown in Table 4 below.

division Control group Low molecular weight alginic acid M / G ratio 1.1 1.6 2.1 2.5 3.2 3.8 The proteoglycan concentration (OD) 0.265 0.278 0.355 0.411 0.436 0.432 0.375 0.245 0.262 0.388 0.414 0.431 0.430 0.404 0.249 0.264 0.395 0.425 0.445 0.446 0.411

As shown in Table 4, it was confirmed that the addition of low molecular weight alginic acid to the control group increased the amount of proteoglycan production. Particularly, as the weight ratio (M / G) of mannuron to glutarate of alginic acid increases, the amount of proteoglycan production increases. Alginic acid having a weight ratio (M / G) of mannuron to glutarate of alginic acid is 2.5 In the case where the weight ratio (M / G) of alginic acid to gluconate was 2.5, the weight ratio (M / G) of alginic acid to glutarate of alginic acid was 2.5 , But it was confirmed that the amount of proteoglycan was remarkably decreased again when the weight ratio (M / G) of mannuronate to glutarate of alginic acid was 3.8.

From the above results, it was confirmed that the weight ratio (M / G) of gluconate to mannuronate was higher in the range of 1.6 to 3.8 than in the case of no addition of alginic acid or addition of polymeric alginic acid as identified in Example 3, and the proteoglycan (M / G) suitable for promoting the production of gluconate was found to be remarkably superior to the case where the weight ratio (M / G) of the gluconate to mannuron was in the range of 2.1 to 3.2, more specifically in the range of 2.5 to 3.2, It was confirmed that the weight ratio (M / G) of rhonate-versus-mannuronate was 2.5, which is the most excellent proteoglycan production promoting ability.

Example  7: Effectiveness Analysis of Osteoarthritis Treatment Using Animal Model

Example  7-1: Breeding of experimental animals

30 New Zealand white rabbits weighing 3 kg to 3.5 kg (New Zealand white rabbit, Magnetic Res., Korea Life Science Research Institute, Korea) were divided into 6 groups of 5 each, and were raised in separate iron cages. The breeding of the experimental animals was carried out from 7:00 am to 7:00 pm under a constant light and dark cycle, at a temperature of 21 ° C to 25 ° C and a relative humidity of 45% to 65% Dry food (Korea Experimental Animals, Korea) was used, and feed and water were constantly available.

Example  7-2: Osteoarthritis  Measuring efficacy of treatment

To confirm the therapeutic effect of osteoarthritis, osteoarthritis was induced in the experimental animals raised in Example 6-1. The osteoarthritis was induced by anterior cruciate ligament resection of the right fuji.

Specifically, 3 mg / kg of xylazine hydrochloride and 50 mg / kg of ketamine hydrochloride were intramuscularly anesthetized, and the right feces were epilated. Then, a 70% aqueous alcohol solution and 10 % Povidone-iodine solution. Of the right epiphysis that had undergone epilation and disinfection, the medial side of the knee was incised 2 cm, the fascia and the capsular incision were made, and the patella was exposed to the outside to expose the anterior cruciate ligament. The exposed anterior cruciate ligament was excised using a No. 11 blade and then rinsed with physiological saline. After the anterior cruciate ligament resection, the patella was placed, the capsular sac and fascia were interrupted with 4-0 absorbable sutures, and the skin was continuously and intermittently sutured with a 3-0 nonabsorbable suture. After the suture was disinfected with the 10% povidone-iodine solution, an antibiotic (enrofloxacin) was injected subcutaneously at a dose of 5 mg / kg (body weight of the experimental animals).

Alginate was orally administered to the experimental animals caused by osteoarthritis. Oral administration was performed by bending into 5 groups. In the control group, low-molecular alginate (Mw) having a mass average molecular weight (Mw) of 2,500 in Example 1 was administered with mannuronate (M) and 0.5 ml / kg (M / G) of guluronate (G) in the same manner as in Examples 5 and 6 above. Specifically, the low molecular weight alginate administered group having an M / G ratio of 1.1, the low molecular weight alginic acid administered group having an M / G ratio of 1.6, the low molecular weight alginic acid administered group having an M / G ratio of 2.5, the low molecular weight alginic acid administered group having an M / G ratio of 3.2, 3.8 Alginic acid was classified into low molecular weight alginic acid group and each alginic acid 30 mg / kg (BW) was dissolved in 0.5 ml / kg (BW) physiological saline.

All of the control and experimental groups were orally administered daily from the next day to the fifth week after surgery.

After 5 weeks of oral administration, all experimental animals belonging to the control group and the experimental group were anesthetized with xylazine and ketamine at 6 weeks after the operation, thyopental sodium was injected intracardially and euthanized, and then the knee joint was exposed The joint surfaces of the middle femur and lateral femur were visually observed. Specifically, the depth of the cartilage defect was confirmed on the inside and outside of the femoral joint by applying the Indian ink to the joint surface of the exposed femur, and the severity of osteoarthritis was divided into four stages of 1 to 4 .

Specifically, 1 indicates a state in which the joint surface appears normal and no ink is applied, 2 indicates a normal appearance, but indicates that the ink is applied in the form of light gray spots upon application of ink, 3 indicates that the joint surface is irritable, 4 indicates the appearance of the cartilaginous bone.

After the scores were measured, the average of five experimental results was calculated for each group. Two observers performed a double blind test for objective comparison. Photographs of the observed cartilage defect regions of the experimental animals are shown in FIGS. 1 to 6, and the calculated average values are shown in Table 5 below.

division Control group Low molecular weight alginic acid M / G ratio 1.1 1.6 2.5 3.2 3.8 Middle femur 3.65 ± 0.8 3.25 ± 0.5 2.90 ± 0.3 2.52 ± 0.3 2.62 ± 0.3 3.05 ± 0.4 Side femur 3.42 ± 0.5 3.16 ± 0.6 2.75 ± 0.5 2.22 ± 0.3 2.18 ± 0.3 2.98 ± 0.4 Total average 3.54 0.7 3.21 ± 0.7 2.82 ± 0.4 2.37 ± 0.3 2.40 ± 0.3 3.02 ± 0.4

As shown in Fig. 1 and Table 5, when the low molecular weight alginic acid was added, a remarkable decrease in the severity of osteoarthritis was observed as compared with the control (Fig. 1).

Specifically, a control group (FIG. 1) in which saline solution was administered with no alginate in the range of 1.6 to 3.8 (M / G) of mannuron to mannuronate versus gluconate (FIG. 3 to FIG. 6) A significant decrease in the degree of osteoarthritis severity was observed as compared with the addition of alginic acid in which the weight ratio (M / G) of contrast-only nuronate was 1.1 (FIG. 2), and the weight ratio (M / G) of gluconate- 4) to 3.2 (FIG. 5), and the weight ratio (M / G) of gluconate to mannuronate was 2.5 (FIG. 4) It was confirmed that the damaged area of the entire cartilage was clearly improved, and thus it was confirmed to have the most excellent effect of improving osteoarthritis.

The result of Example 7 using the above animal model was confirmed that the result of the same tendency as in Example 5 and Example 6, make a collagen production-accelerating performance and proteoglycans production-accelerating function in vitro (invitro).

Claims (15)

A pharmaceutical composition for treating or preventing osteoarthritis comprising alginic acid as an active ingredient. The method according to claim 1,
Wherein the alginic acid has an average weight-average molecular weight (Mw) of alginic acid of 1,500 to 5,000, and a weight ratio (M / G) of mannuronate of alginic acid and gluronate is 1.6 to 3.8. 3. The method of claim 2,
Wherein the alginic acid is a mixture of mannuronate of alginic acid and gluronate (M / G) in a weight ratio of 2.0 to 3.4. The method of claim 3,
Wherein the alginic acid has a weight ratio (M / G) of mannuronate of alginic acid to glutarate of 2.3 to 2.7. The method according to claim 1,
Wherein the alginic acid is a mixture of mannuronate of alginic acid and gluronate in a weight ratio (M / G) of 1.6 to 3.8. 6. The method of claim 5,
Wherein the alginic acid is a mixture of mannuronate of alginic acid and gluronate (M / G) in a weight ratio of 2.0 to 3.4. The method according to claim 6,
Wherein the alginic acid has a weight ratio (M / G) of mannuronate of alginic acid to glutarate of 2.3 to 2.7. A food composition for preventing or improving osteoarthritis comprising alginic acid having a weight ratio (M / G) of mannuronate of alginic acid and gluronate of 1.6 to 3.8 as an active ingredient. 9. The method of claim 8,
Wherein the alginic acid has an average weight average molecular weight (Mw) of 1,500 to 5,000. 9. The method of claim 8,
Wherein the food composition is a food, a food additive or a beverage. A pharmaceutical composition for treating or preventing osteoporosis, which comprises alginic acid having a weight ratio (M / G) of mannuronate of alginic acid to gluronate of 1.6 to 3.8 as an active ingredient. 12. The method of claim 11,
Wherein the alginic acid has an average weight average molecular weight (Mw) of 1,500 to 5,000. A food composition for preventing or improving osteoporosis, which comprises alginic acid having a weight ratio (M / G) of mannuronate of alginic acid and gluronate of 1.6 to 3.8 as an active ingredient. 14. The method of claim 13,
Wherein the alginic acid has an average weight average molecular weight (Mw) of 1,500 to 5,000. 14. The food composition according to claim 13, wherein the food composition is food, food additive or beverage.

Images